Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 190 papers
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters
6/2012 - Upton AM, Cho S, Yang TJ, et. al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14.
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs
4/2012 - Dutta NK, Illei PB, Peloquin CA, et. al. Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea Pigs. http://aac.asm.org/content/56/7/3726.long. Accessed March 7, 2016
Systematic Evaluation of Structure-Activity Relationships of the Riminophenazine Class and Discovery of a C2 Pyridylamino Series for the Treatment of Multidrug-Resistant Tuberculosis
4/2012 - Liu B, Liu K, Yang TJ, et. al. Systematic evaluation of structure-activity relationships of... Molecules. 2012 Apr 17;17(4):4545-59. doi: 10.3390/molecules17044545.
Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
4/2012 - Williams K, Minkowski A, Amoabeng O, et. al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12.
Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery
3/2012 - Coxon GD, Cooper CB, Gillespie SH, McHugh TD. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J Infect Dis. 2012 May 15;205 Suppl 2:S258-64. doi: 10.1093/infdis/jis191.
Phase II dose-ranging trial of the early bactericidal activity of PA-824
3/2012 - Diacon AH, Dawson R, du Bois J, et. al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11
Moxifloxacin for tuberculosis
3/2012 - Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.
New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
3/2012 - Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.
Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1)
2/2012 - Harikrishnan LS, Srivastava N, Kayser LE, et. al. Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1). Bioorg Med Chem Lett. 2012 Mar 15;22(6):2287-90. doi: 10.1016/j.bmcl.2012.01.082.
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
12/2011 - Blaser A, Palmer BD, Sutherland HS, et. al. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J
Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation
11/2011 - Yu Lu, Meiqin Zheng, Bin Wang, et. al. Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation. Antimicrob Agents Chemother. 2011 Nov; 55(11): 5185–5193. doi: 10.1128/AAC.00699-11
Structural insight into serine protease Rv3671c that Protects M. tuberculosis from oxidative and acidic stress
10/2011 - Biswas T, Small J, Vandal O, et. al. Structural insight into serine protease Rv3671c that protects M. tuberculosis from oxidative and acidic stress. Structure. 2010 Oct 13;18(10):1353-63. doi: 10.1016/j.str.2010.06.017.
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis
9/2011 - Tasneen R, Li SY, Peloquin CA, et. al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
9/2011 - Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0.
Synthesis and Structure-activity Relationships of Varied Ether Linker Analogues of the Anti-tubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (
9/2011 - Thompson AM, Sutherland HS, Palmer BD, et. al. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
Challenges and opportunities in developing novel drugs for TB
9/2011 - Kaneko T, Cooper C, Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem. 2011 Sep;3(11):1373-400. doi: 10.4155/fmc.11.115.
Drugs for neglected diseases: part II
9/2011 - Kaneko T. Drugs for neglected diseases: part II. Future Med Chem. 2011 Sep;3(11):1329-30. doi: 10.4155/fmc.11.104.
Drug repositioning in the treatment of malaria and TB
9/2011 - Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem. 2011 Sep;3(11):1413-26. doi: 10.4155/fmc.11.95.
The TB Alliance: overcoming challenges to chart the future course of TB drug development
8/2011 - Ginsberg AM. The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem. 2011 Aug;3(10):1247-52. doi: 10.4155/fmc.11.82.
Drugs for neglected diseases: part I
8/2011 - Kaneko T. Drugs for neglected diseases: part I. Future Med Chem. 2011 Aug;3(10):1235-7. doi: 10.4155/fmc.11.103.